What Happened to R3 Bio?

R3 Bio, a biotechnology company headquartered in Boston, Massachusetts, and operating from Richmond, California, has emerged as a significant, albeit controversial, player in the field of regenerative medicine. Founded by John Schloendorn, the company's publicly stated mission centers on developing advanced stem cell-derived biological platforms, referred to as 'bodyoids' or 'organ sacks,' to replace traditional animal testing in preclinical drug discovery and regenerative medicine. These platforms are designed as integrated tissue systems that replicate whole-organism biological dynamics without brain support, aiming to improve translational relevance and address ethical concerns associated with animal experimentation.

The controversy surrounding R3 Bio intensified in March 2026, when an investigation by MIT Technology Review revealed a stark contrast between the company's public narrative and its alleged private ambitions. According to the investigation, Schloendorn has privately pitched a vision of creating 'brainless human clones'—cloned human bodies engineered with minimal brain structure—to serve as immunologically perfect sources for organ transplants or, ultimately, as hosts for brain transplants to achieve radical life extension for wealthy individuals. Records from a high-priced longevity event in Boston in September 2025 reportedly show Schloendorn presenting a session titled 'Full Body Replacement.'

R3 Bio has vehemently denied these allegations, with COO Alice Gilman stating that the company's work involves molecules, cell cultures, and microscopic structures, and that they do not condone claims of working on large-scale 'organ sacks' or 'brainless animals.' She clarified that while R3's current business is replacing animal models, the team reserves the right to hold hypothetical futuristic discussions. Despite the denials, the reports highlight significant investment interest from figures like American billionaire Tim Draper and Singaporean investment fund Immortal Dragons, who are reportedly backing R3 Bio's vision.

Critics and bioethicists have raised profound ethical concerns regarding the concept of creating brainless human clones, questioning the definition of human life and the potential for exploitation. The scientific community also notes a vast 'science gap' between R3 Bio's ambitious vision and current capabilities; as of March 2026, the company has not cloned anything larger than a rodent, and scaling to primates or engineering brain-suppressed human clones remains well beyond demonstrated scientific capability. The situation underscores the intersection of rapidly advancing longevity science, significant capital flows, and a regulatory environment struggling to keep pace with novel biotechnologies.

As of March 31, 2026, R3 Bio continues its exploratory research into integrated bio platform models to strengthen translational relevance and contribute to advancing life-saving therapies through responsible scientific design. The company's 2026 research report, released in March, detailed early-stage progress in developing stem cell-derived biological platforms to reduce reliance on animal testing. The debate over its ultimate goals and ethical boundaries remains a prominent topic in the scientific and public spheres.